Advances in the biology and treatment of myeloma bone disease

被引：24

作者：

Berenson, JR ^{[1
]}

机构：

[1] Univ Calif Los Angeles, Sch Med, Cedars Sinai Med Ctr, Multiple Myeloma & Bone Metastasis Program, Los Angeles, CA 90402 USA

来源：

SEMINARS IN ONCOLOGY | 2002年 / 29卷 / 06期

关键词：

D O I：

10.1053/sonc.2002.34071

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The major clinical manifestations of multiple myeloma are related to the loss of bone. This bone loss often leads to pathologic fractures, spinal cord compression, hypercalcemia, and bone pain. This article reviews the cytokine network involved in myeloma bone disease; describes the signaling cascade involved in osteoclasto-genesis and mechanisms of action of novel therapeutic options for myeloma bone disease such as osteoprotegerin, RANK human immunoglobulin fusion protein, the proteasome inhibitor PS-341, and bisphosphonates; and summarizes the latest clinical trial results using oral and intravenous bisphosphonates for bone disease in multiple myeloma. Copyright 2002, Elsevier Science (USA). All rights reserved.

引用

页码：11 / 16

页数：6

共 14 条

[1]

ALTAMIRANO CV, 2001, AM SOC HEM 43 ANN M

[2] EFFECT OF DAILY ETIDRONATE ON THE OSTEOLYSIS OF MULTIPLE-MYELOMA [J].

BELCH, AR ;

BERGSAGEL, DE ;

WILSON, K ;

OREILLY, S ;

WILSON, J ;

SUTTON, D ;

PATER, J ;

JOHNSTON, D ;

ZEE, B .

JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (08) :1397-1402

[3]

Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO

[4]

2-0

[5] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma [J].

Berenson, JR ;

Lichtenstein, A ;

Porter, L ;

Dimopoulos, MA ;

Bordoni, R ;

George, S ;

Lipton, A ;

Keller, A ;

Ballester, O ;

Kovacs, MJ ;

Blacklock, HA ;

Bell, R ;

Simeone, J ;

Reitsma, DJ ;

Heffernan, M ;

Seaman, J ;

Knight, RD .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) :488-493

[6] Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial [J].

Brincker, H ;

Westin, J ;

Abildgaard, N ;

Gimsing, P ;

Turesson, I ;

Hedenus, M ;

Ford, J ;

Kandra, A .

BRITISH JOURNAL OF HAEMATOLOGY, 1998, 101 (02) :280-286

[7]

CROUCHER P, 2001, AM SOC HEM 43 ANN M

[8]

GREIPP P, 2001, AM SOC HEM 43 ANN M

[9] RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL OF CLODRONATE IN MULTIPLE-MYELOMA [J].

LAHTINEN, R ;

LAAKSO, M ;

PALVA, I ;

VIRKKUNEN, P ;

ELOMAA, I .

LANCET, 1992, 340 (8827) :1049-1052

[10] Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials [J].

Major, P ;

Lortholary, A ;

Hon, J ;

Abdi, E ;

Mills, G ;

Menssen, HD ;

Yunus, F ;

Bell, R ;

Body, J ;

Quebe-Fehling, E ;

Seaman, J .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :558-567

← 1 2 →